Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 2/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12586113 | 0.95 | EPHX2 (0.41) | EPHX2CYP19A1LMNAL3MBTL1GRM5 | |
| SCHEMBL20033743 | 0.93 | CYP19A1 (0.41) | EPHX2CYP19A1LMNAL3MBTL1GRM5 | |
| SCHEMBL14943252 | 0.90 | CYP19A1 (0.38) | EPHX2CYP19A1LMNAL3MBTL1GRM5 | |
| SCHEMBL4306573 | 0.75 | ESR1 (0.46) | CYP19A1LMNAL3MBTL1CHKASIGMAR1 | |
| SCHEMBL353050 | 0.75 | OPRL1 (0.46) | — | |
| SCHEMBL16590522 | 0.74 | ALDH1A1 (0.40) | EPHX2LMNAMAPTTSHRHSD17B10 | |
| SCHEMBL10602015 | 0.74 | ESR1 (0.42) | L3MBTL1 | |
| SCHEMBL8297897 | 0.73 | MAOB (0.40) | L3MBTL1MAPTHSD11B1 | |
| SCHEMBL436499 | 0.71 | SLC6A4 (0.46) | EPHX2LMNAMAPTHSD11B1TSHR | |
| SCHEMBL19779259 | 0.71 | VNN1 (0.31) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11709427-B2 | Positive resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-07-25 | — | — | US | disclosed |
| US-11709427-B2 | Positive resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-07-25 | — | — | US | disclosed |
| US-20210247694-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-08-12 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | EPHX2 1915/4885CYP19A1 990/4885LMNA 1478/4885 |
| US-11709427-B2 | Positive resist composition and pattern forming process | EWSR1, PARG, VIM | EPHX2 4575/4885CYP19A1 3736/4885LMNA 2542/4885 |
| US-20210247694-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | EWSR1, PARG, VIM | EPHX2 4575/4885CYP19A1 3736/4885LMNA 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.